On 2015 Oct 05, S Sundar commented:

ARV-7 dynamics and re-induction of hormone sensitivity by chemotherapy in Prostate cancer.

This report by Antonarakis’s group regarding reversal of ARV-7 positivity by Taxane chemotherapy is likely to have a significant impact on the sequencing of various hormonal and chemotherapeutic agents .

The two previous independent reports of re- induction of hormone sensitivity by chemotherapy could probably be explained by this mechanism whereby chemotherapy induces favourable changes for hormone therapy to be effective again after prior hormonal resistance[1][2].

The previous reports of re-induction of hormone sensitivity by chemotherapy utilised Docetaxel monotherapy as well as Chlorambucil and Lomustine combination therapy. Hence it could be hypothesised that the reversal of ARV-7 dynamics and consequent re-induction of hormone sensitivity is a class effect of chemotherapy induced selection pressure. Exploitation of this phenomenon would significantly optimise the use of existing hormonal and chemotherapeutic agents in prostate cancer.

References:

1. Cox RA, Sundar S. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy. Br. J. Cancer 2008; 98(1):238–239.

2. Shamash J, Davies A, Ansell W et al. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br. J. Cancer 2008; 98(1):22–24.

On 2015 Oct 05, S Sundar commented:

ARV-7 dynamics and re-induction of hormone sensitivity by chemotherapy in Prostate cancer.

This report by Antonarakis’s group regarding reversal of ARV-7 positivity by Taxane chemotherapy is likely to have a significant impact on the sequencing of various hormonal and chemotherapeutic agents .

The two previous independent reports of re- induction of hormone sensitivity by chemotherapy could probably be explained by this mechanism whereby chemotherapy induces favourable changes for hormone therapy to be effective again after prior hormonal resistance[1][2].

The previous reports of re-induction of hormone sensitivity by chemotherapy utilised Docetaxel monotherapy as well as Chlorambucil and Lomustine combination therapy. Hence it could be hypothesised that the reversal of ARV-7 dynamics and consequent re-induction of hormone sensitivity is a class effect of chemotherapy induced selection pressure. Exploitation of this phenomenon would significantly optimise the use of existing hormonal and chemotherapeutic agents in prostate cancer.

References:

1. Cox RA, Sundar S. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy. Br. J. Cancer 2008; 98(1):238–239.

2. Shamash J, Davies A, Ansell W et al. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br. J. Cancer 2008; 98(1):22–24.